CME Corner

Program Detail

Release Date: October-01-19
Credit Expiration Date: October-01-20


Scott Kahan, MD, MPH
Director, National Center for Weight and Wellness
Medical Director, Strategies To Overcome and Prevent (STOP) Obesity Alliance
George Washington University Milken Institute School of Public Health
Chair, Clinical Committee, The Obesity Society
Washington, DC

Ken Fujioka, MD
Director, Nutrition and Metabolic Research Center
Scripps Clinic, Dept. of Endocrinology, Diabetes, and Metabolism
San Diego, CA

Credit Hours



Mobile + Online on RealCME

Program Description

Obesity is a chronic, complex disease with a significant economic burden that is associated with more than 200 other medical disorders that affect entire organ systems. The National Center for Health Statistics (NCHS) recently reported that the prevalence of obesity in US adults is nearly 40%. It is now recognized by the World Health Organization (WHO) as an epidemic, with an estimated 671 million people worldwide classified as obese. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a motivated patient and a committed team of health professionals. This series will examine a comprehensive, patient-centered, multidisciplinary approach to obesity that includes shared decision-making to improve patient outcomes.

Program Developer/Facilitator


Target Audience

Primary care physicians, endocrinologists and other members of the care team involved in the management of obese patients, including nurse practitioners (NPs), physician assistants (PAs), and nurses.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Summarize physiological mechanisms involved in obesity and weight loss.
  2. Relate the impact of excess weight to morbidity and mortality, particularly with regard to type 2 diabetes, cardiovascular disease, and certain cancers.
  3. Review current guidelines for obesity management.
  4. Outline the approved anti-obesity medications and their mechanisms of action, efficacy, and safety.
  5. Describe the assessment of a patient with moderate obesity and development of a treatment plan.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.

Dr. Kahan discloses the following:
Consultant: Amgen, Bausch, Biologix, Novo Nordisk, Orexigen, Vivus

Dr. Fujioka discloses the following:
Research Grant: Eisai
Consultant: Amgen, Boehringer-Ingelheim, Eisai, Gelesis, Janssen Global Services, KVK-tech, Novo Nordisk, Sunovion
Speakers Bureau: Novo Nordisk

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by an educational grant from Novo Nordisk, Inc.

Certificate Fee



© 2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu